(Q36802630)

16 August 2017

1 reference

title

Tafenoquine: a promising new antimalarial agent (English)

1 reference

16 August 2017

0 references

2

Kevin C Kain

1 reference

16 August 2017

Maryanne Crockett

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

705-715

1 reference

The global distribution of clinical episodes of Plasmodium falciparum malaria

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Malaria: Current status of control, diagnosis, treatment, and a proposed agenda for research and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Effectiveness of antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Malaria chemoprophylaxis with tafenoquine: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Measurement of tafenoquine (WR 238605) in human plasma and venous and capillary blood by high-pressure liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Clinical pharmacokinetics of antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

The efficacy of WR238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Treatment of acute vivax malaria with tafenoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Antimalarial Drug Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

A systematic overview of published antimalarial drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.705

10.1517/13543784.16.5.705

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference